ABOSInvestor Conferences•globenewswire•
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Sentiment:Negative (20)
Summary
NEWTON, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in the following upcoming investor conferences.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 26, 2025 by globenewswire